Embedded Files
Universal Cancer-Specific Drugs and Universal Early Stage Cancer Screening
# Vision and Mission:
Universal cancer-specific drugs and Universal tumor-specific imaging agents.
Universal early stage cancer screening to cut tumors away, making cancer cured easily.
Real-time therapy resistance detection. Guiding correct therapy. Preventing patients from taking ineffective drugs.
Guiding precision dosing. Reducing drug side-effects in cancer therapy.
Detecting early cancer relapse to timely treat it.
Real-time cancer action detection.
The world’s first truly Universal Cancer-Specific (UCS) platform
1. Core Innovation
We have pioneered a revolutionary method to produce Universal Cancer-Specific drugs, targeting an antigen that is exceptionally overexpressed across all cancer stages—from early-stage adenomas to advanced malignancies—across all cancer types. Our technology bypasses the limitations of current personalized medicine, offering a disruptive "One Drug, All Cancers" paradigm.
2. Technological Ecosystem
Our patented platform enables the rapid development of a comprehensive anti-cancer arsenal, including:
(1) Next-Gen Therapeutics: UCS-ADCs, Radio-pharmaceuticals, Bispecific Antibodies, and CAR-T/CAR-NK cell therapies.
(2) Curative Vaccines: Universal cancer vaccines designed to eliminate systemic tumors and prevent relapse.
(3) AI-Driven Diagnostics: Universal tumor-specific imaging agents that, paired with our AI algorithms, detect occult small metastases and early-stage lesions currently invisible to standard diagnostics.
3. Global Impact & IP Security
To ensure long-term global commercial rights and patient access, we have filed extensive patent applications worldwide, securing 20 years of intellectual property protection. By targeting biomarkers with extremely high expression in metastatic cells and early lesions, our technology is engineered to maximize efficacy while minimizing resistance and relapse, setting a new gold standard for AI-driven Precision Oncology.
4. Tumor signal transductions stimulate cancer progression; it takes time less than 1 hour and continuously. We create a novel medical field “Tumor Signal Transduction-Liquid Biopsy” to assay tumor intracellular signal transduction in blood.
(1) Screen early stage cancers to cut tumors away, making cancer cured easily.
(2) Detect therapy resistance in real-time. Guide correct therapy. Prevent patients from taking ineffective drugs.
(3) Guide precision dosing in real-time. Reduce drug side-effects.
(4) Detect early cancer relapse, to timely treat it.
(5) Make real-time cancer action detection possible.
Invention-1: Tumor Signal Transduction-Liquid Biopsy
Clinical Trials
Competitive Analysis
Invention 2: Universal Cancer-Specific (UCS) platform
(Intelligent property secret)
Contact: jiangmwd@gmail.com
Page updated
Google Sites
Report abuse